We are a world-leading cancer research institute, a charity, and a member institution of the University of London. Public donations and clinical partnerships are helping us to make the discoveries ...

Nia Haware and Marcia Pennant work jointly as Legacy Marketing Officers in our Development and Communications Office.

Twenty years ago today, the International Genome Sequencing Consortium published the first detailed analysis of the human genome. The paper appeared online in Nature on 15 February 2001, followed by a ...

These days, in the era of personalised medicine, whenever researchers discover a new cancer drug they are expected to show exactly how it works and to prove that it is exerting its therapeutic effect ...

One year of treatment with the targeted drug olaparib improves long-term survival in women with high-risk, early-stage breast cancer with mutations in BRCA1 or BRCA2 genes, new results from a major ...

The overuse of CT scans could cause over 100,000 cases of cancer in the US – with almost 10,000 cases in children, researchers have warned. According to a new modelling study, published in the journal ...

The Institute of Cancer Research, London, strongly welcomes the decision by NICE to recommend the targeted breast cancer drug, capivasertib, in combination with fulvestrant, for treating the most ...

Scientists have discovered a key protein that could be targeted with a drug to treat the most common and aggressive form of pancreatic cancer. The findings, published in Nature, show that blocking the ...

Image: Person walking towards the beach. Credits: Pixabay. Most people are aware of the benefits of exercise – it has been associated with improvements in overall health for some time. It makes sense ...

New research presents clear guidelines on how patient-reported outcomes (PROs) can be used more effectively in early-stage cancer drug trials, helping ensure that patient experiences meaningfully ...

Two decades ago, a pivotal exchange between two scientists sparked a scientific and medical revolution. Professor Alan Ashworth, then Director of the Breast Cancer Now Toby Robins Research Centre at ...

We share the story of a pioneering and collaborative research programme at the ICR, initiated in the late 1990s, that led to one of the first clinical-stage PI3K inhibitors, laying the foundation for ...